Wilson J L, Cunningham A C, Kirby J A
Department of Surgery, Medical School, University of Newcastle upon Tyne, UK.
Immunology. 1995 Nov;86(3):325-30.
This paper describes a model for investigation of the functional implications of B-cell activation for antigen presentation. Mixed lymphocyte cultures were used to assess the ability of freshly isolated B cells, mitogen-activated B cells and Epstein-Barr virus (EBV)-transformed B-cell lines to stimulate the activation and proliferation of allogeneic T cells under a variety of experimental conditions. It was found that resting B cells presented antigen poorly, while activated cells were highly immunogenic. Paraformaldehyde fixation completely eliminated antigen presentation by resting B cells, despite constitutive expression of class II MHC antigens. However, fixation had little effect on antigen presentation by activated B cells that expressed B7-1 and B7-2 in addition to class II major histocompatibility complex (MHC) molecules. Arrest of B-cell activation by serial fixation after treatment with F(ab')2 fragments of goat anti-human IgM produced cells with variable antigen-presenting capacity. Optimal antigen presentation was observed for cells fixed 72 hr after the initiation of B-cell activation. Although both B7-1 and B7-2 antigen expression increased after B-cell activation, it was found that the rate of T-cell proliferation correlated most closely with B7-2 expression. Stimulation of T cells by fixed activated B lymphocytes could be blocked by antibodies directed at class II MHC molecules, indicating involvement of the T-cell antigen receptor. In addition, T-cell proliferation was inhibited by antibodies specific for B7-1 and B7-2 and by the fusion protein CTLA4-Ig, demonstrating a requirement for CD28 signal transduction. The sole requirement of B7 family expression for antigen presentation by B lymphocytes was shown by demonstration of T-cell stimulation by fixed resting B cells in the presence of CD28 antibody as a source of artificial costimulation.
本文描述了一个用于研究B细胞激活对抗抗原呈递功能影响的模型。混合淋巴细胞培养用于评估新鲜分离的B细胞、丝裂原激活的B细胞和爱泼斯坦-巴尔病毒(EBV)转化的B细胞系在各种实验条件下刺激同种异体T细胞激活和增殖的能力。研究发现,静止B细胞的抗原呈递能力较差,而激活的细胞具有高度免疫原性。尽管静止B细胞组成性表达II类MHC抗原,但多聚甲醛固定完全消除了其抗原呈递能力。然而,固定对除II类主要组织相容性复合体(MHC)分子外还表达B7-1和B7-2的激活B细胞的抗原呈递影响不大。用山羊抗人IgM的F(ab')2片段处理后进行连续固定以阻止B细胞激活,产生了抗原呈递能力各异的细胞。在B细胞激活开始后72小时固定的细胞观察到最佳抗原呈递。尽管B细胞激活后B7-1和B7-2抗原表达均增加,但发现T细胞增殖速率与B7-2表达最密切相关。固定的激活B淋巴细胞对T细胞的刺激可被针对II类MHC分子的抗体阻断,表明T细胞抗原受体参与其中。此外,B7-1和B7-2特异性抗体以及融合蛋白CTLA4-Ig可抑制T细胞增殖,证明需要CD28信号转导。通过在存在作为人工共刺激源的CD28抗体的情况下固定的静止B细胞对T细胞的刺激,证明了B7家族表达是B淋巴细胞抗原呈递的唯一要求。